Pharmacovigilance of Drug-Drug Interactions with Nirmatrelvir/Ritonavir.

ABSTRACT:

Introduction

Nirmatrelvir/ritonavir (NMV/r) is approved in the United States (US) and more than 70 other countries for the treatment of mild to moderate COVID-19 in nonhospitalized adults at high risk for severe disease. Because ritonavir inhibits several drug metabolizing enzymes, potential drug-drug interactions (DDIs) between ritonavir and concomitant medications are an important consideration for prescribers. Here, we conducted a real-world analysis of data from Pfizer's global safety database regarding adverse events (AEs) reported during use of NMV/r concomitantly with potentially interacting drugs.

Methods

Data were extracted regarding DDI cases occurring from the start of NMV/r authorization through October 31, 2023. Results regarding concomitant treatment, specific

SUBMITTER: Hendrick V 

PROVIDER: S-EPMC11582113 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature